The notices it replaced
- Reissues: PA-18-575 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 2 steps back: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 3 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 4 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 6 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 10 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 11 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-20-265.
Who won it before
1,360 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $440,802,024 in first-year total cost, median $226,684.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]97
- Special Emphasis Panel[ZRG1 OTC-T (10)]75
- Special Emphasis Panel[ZRG1 ETTN-G (12)]62
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 CVRS-C (10)]42
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC13
- L2 DIAGNOSTICS, LLC11
- MEDOSOME BIOTEC, LLC9
- ARREVUS, INC.7
- MICROBIOTIX, INC7
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Epigenetic Markers and Sustained Cytoprotection for Stroke Treatment2R42NS098918-02A1 | BOOHER, KEITHGUO, WEIHUANG, SHAOLING | ZYMO RESEARCH CORPORATION, CA | $1,082,714 | ZRG1 |
| 2021 | Aminoglycosides with reduced ototoxicity2R42AI126874-03 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $999,986 | ZRG1 |
| 2021 | Development of peptide nucleic acid antibiotics2R42AI114114-03 | ARYA, DEV PRIYA | NUBAD, LLC, SC | $999,985 | ZRG1 |
| 2021 | Multi-Institutional Implementation of Quality Decisions: a Clinical Decision Support Analytics Tool to Drive Outcomes2R42LM013317-02 | ORENSTEIN, EVAN WILLIAM | PHRASE HEALTH, INC., PA | $872,808 | ZRG1 |
| 2021 | Imaging biomarkers of severe respiratory infections in premature infants Phase II2R42HL145669-02A1 | ENQUOBAHRIE, ANDINET ASMAMAWLINGURARU, MARIUS GEORGENINO, GUSTAVO | KITWARE, INC., NY | $852,101 | ZRG1 |
| 2021 | VAL-0914 Decreases PAO to Protect Against Cardiac Proteinopathies1R41HL152919-01A1 | SHAFFER, ROBERTWANG, XUEJUN | ENABLE THERAPEUTICS LLC, MA | $450,022 | ZRG1 |
| 2021 | A New Anti-inflammatory Therapy for Ischemic Stroke1R41HL156322-01 | LIANG, BRUCE | CORNOVUS PHARMACEUTICALS, INC., CT | $433,483 | ZRG1 |
| 2021 | Development of a Therapeutic Monoclonal Antibody Against EGFL6, a Mediator of Tumor Growth and Metastasis1R41CA250757-01A1 | ALLEN, THADDEUS DAVID | TRADEWIND BIOSCIENCE, INC., CA | $405,552 | ZRG1 |
| 2021 | Engineered adipokine receptor inhibitor for the treatment of triple negative breast cancer in obese patients1R41CA257425-01 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $400,000 | ZRG1 |
| 2021 | Development of a biomarker panel for screening and early detection of gynecological cancers1R41CA257115-01 | MARTIGNETTI, JOHN A | MDDX, INC., NY | $399,972 | ZRG1 |
| 2021 | A novel polymer-metal nanocomplex for ovarian cancer treatment1R41CA254500-01A1 | XU, PEISHENG | ACEPRE, LLC, SC | $392,803 | ZRG1 |
| 2021 | Identifying novel targets for cardioprotection with non-traditional animal models1R41HG011577-01 | GOODMAN, LINDA BOETTGER | FAUNA BIO INCORPORATED, CA | $373,434 | ZRG1 |
| 2021 | A Transparent Surgical Mask to Improve Patient/Caregiver Communication, Minimize Errors and Increase Patient Satisfaction2R42NR017124-02 | HAHNE, JEANNE | FACEVIEW MASK, LLC, OR | $359,907 | ZRG1 |
| 2021 | Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.1R43HG011608-01 | BRUECK, STEVEN | ARMONICA TECHNOLOGIES, INC., NM | $349,200 | ZRG1 |
| 2021 | Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotics LR-IL-22 and LR-IFN-β1R41AI157357-01 | GREENBERGER, JOEL SROGERS, CLAUDE J. | CHROMOLOGIC, LLC, CA | $300,000 | ZRG1 |
| 2021 | Use novel natural compound Sparstolonin B to treat bacterial sepsis1R41AI157378-01 | FAN, HONGKUAN | ACEPRE, LLC, SC | $300,000 | ZRG1 |
| 2021 | Biomimetic size-adaptable heart valve for prosthesis-patient mismatch1R41HL156563-01 | DEL NIDO, PEDRO J. | AUTUS VALVE TECHNOLOGIES, INC., MA | $299,994 | ZRG1 |
| 2021 | Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-21R41AI157626-01 | HARTIGAN-O'CONNOR, DENNIS J. | TENDEL THERAPIES INC., CA | $299,983 | ZRG1 |
| 2021 | Multiplexed CRISPR-based immune cell RNA profiling by flow and mass cytometry1R41AI157717-01 | O'CONNELL, MITCHELL | DAHLIA BIOSCIENCES, INC., CA | $299,978 | ZRG1 |
| 2021 | A Novel Broad-spectrum Antiviral Agent1R41AI157527-01 | BOTTEN, JASON W.MURAD, JOANA M | CELDARA MEDICAL, LLC, NH | $299,916 | ZRG1 |
| 2021 | Furopyrimidines as novel inhibitors of henipaviruses1R41AI157095-01 | RONG, LIJUN | CHICAGO BIOSOLUTIONS, INC., IL | $299,595 | ZRG1 |
| 2021 | Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage1R41GM140538-01 | JOHNSON, STEVEN EDWARD | DURAMETRIX LLC, WI | $257,175 | ZRG1 |
| 2021 | Computer-aided design for improved lantibiotics1R41GM136034-01A1 | HANDFIELD, MARTIN | ORAGENICS, INC., FL | $256,654 | ZRG1 |
| 2021 | An Innovative Screener for Reading and SLI targeting Kindergarten through 3rd Grade Students1R43DC018766-01A1 | ANGEL, MARKRICE, MABEL L | AMIRA LEARNING, INC., CA | $256,580 | ZRG1 |
| 2021 | Novel Ophthalmic Product for Corneal Infections and Injuries1R41EY032437-01 | PEREIRA, HELOISE ANNE | BIOLYTX PHARMACEUTICALS CORP, OK | $256,580 | ZRG1 |
| 2021 | PHMB-Impregnated Acellular Biologic Grafts for Treatment of Third-Degree Burns1R41GM140660-01 | PASHOS, NICHOLAS | BIOAESTHETICS CORPORATION, NC | $256,069 | ZRG1 |
| 2021 | A Peptide-Based Polyplex Platform for Nucleotides Delivery to the Sites of Inflammation1R41TR003244-01A1 | WICKLINE, SAMUEL A | TRASIR THERAPEUTICS, INC., FL | $254,092 | ZRG1 |
| 2021 | Developing a RPN13 inhibitor for the treatment of Quadruple Negative Breast Cancer1R41CA257110-01 | ANCHOORI, RAVI KUMAR | UP THERAPEUTICS, INC., MD | $253,516 | ZRG1 |
| 2021 | X-ray Visualized Interbody Spacer Indicating Biomechanical Load (X-VISIBL) Fusion Device1R41AR078137-01A1 | DESJARDINS, JOHN DAVIDLORE, VITO | SPINEFRONTIER, INC., MA | $252,127 | ZRG1 |
| 2021 | Pediatric Heart Valve with Expansion Capability1R41HL154972-01A1 | SIERAD, LESLIE NEIL | APTUS, LLC, SC | $252,127 | ZRG1 |
| 2021 | A Chemiluminescent Assay and Device for Monitoring Vascular Endogenous Nitric Oxide1R41GM140575-01 | LIPPERT, ALEXANDER RYAN | BIOLUM SCIENCES, LLC, TX | $251,943 | ZRG1 |
| 2021 | Multi-stable Compliant-Mechanism-based Mattress for Bedsore Prevention1R41NR019721-01 | HOPKINS, JONATHAN | K MEDICAL LLC, CA | $251,440 | ZRG1 |
| 2021 | Milling with Ultraviolet Excitation for Whole Organ Cellular-Level Phenotyping1R41GM140586-01 | WOMACK, TASHA | SWIFT FRONT, LLC, TX | $251,417 | ZRG1 |
| 2021 | Imaging Bacterial Infections in Vivo: First in Man Studies1R42AI157552-01 | GOODMAN, MARK MYRON | MICROBIAL IMAGING, LLC, GA | $228,484 | ZRG1 |
| 2021 | BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline1R41AG071290-01 | HALTER, RYAN JOSEPH | SYNCHROHEALTH LLC, NH | $224,700 | ZRG1 |
| 2021 | HB-EGF regeneration to treat oral aphthous ulcers1R41DE030043-01 | MCGRAW, BENJAMIN FRANKLINSANTA MARIA, PETER LUKE | AURATION BIOTECH, INC., NC | $200,240 | ZRG1 |
| 2021 | Intravenous ivermectin for sepsis1R41AI156935-01 | HASKO, GEORGE | PURINE PHARMACEUTICALS, INC., NJ | $193,829 | ZRG1 |
| 2021 | Developing a novel drug for neurobehavioral deficits in FASD1R41AA029025-01 | TORII, MASAAKI | COGTHERA, LLC, MD | $164,683 | ZRG1 |
| 2020 | Enabling self-reported outcomes for youth with developmental disabilities: The Pediatric Evaluation of Disability Inventory - Patient Reported Outcome (PEDI-PRO) - Phase II2R42HD090772-03A1 | DAVIES, DANIEL KKRAMER, JESSICA MARVELLE | ABLELINK TECHNOLOGIES, INC., CO | $1,520,155 | ZRG1 |
| 2020 | Omniphobic cerebral shunt to eliminate clogging and dysfunction2R42NS103704-02A1 | BANDYOPADHYAY, SAIBALHARRIS, CAROLYN AMCALLISTER, JAMES PATTERSON | CERULEAN SCIENTIFIC INC., PA | $1,384,382 | ZRG1 |
| 2020 | Catheter Based Cardiovascular Device Retrieval System2R42HL139309-02 | GORMAN, JOSEPH H | ONOCOR, LLC, PA | $1,270,287 | ZRG1 |
| 2020 | Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to AD2R42AG053149-02A1 | LI, JINGLURE, FLEMING Y. M. | MS TECHNOLOGIES CORPORATION, MD | $1,252,970 | ZRG1 |
| 2020 | A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization2R42CA213909-02A1 | HUNTER, WILLIAM COULIS JASON | PET/X, LLC, WA | $1,231,107 | ZRG1 |
| 2020 | Robust Predictor of Breast Cancer Risk2R42CA217383-02A1 | OSTRER, HARRY | MORGAN AND MENDEL GENOMICS, INC., DE | $991,797 | ZRG1 |
| 2020 | A small molecule integrin activator to enhance cord blood transplant2R42HL129612-02 · under PA-18-575 | MARATHI, UPENDRAVANDERSLICE, PETER | 7 HILLS PHARMA, LLC, TX | $935,957 | ZRG1 |
| 2020 | Development of novel Amadorins for Diabetic Peripheral Neuropathy2R42DK120063-02 | KHALIFAH, RAJA G | PRAETEGO, INC., NC | $874,423 | ZRG1 |
| 2020 | EpiZode: Noninvasive Seizure Screening in Preclinical Models of Epilepsy2R42NS107148-02 | SUNDERAM, SRIDHAR | SIGNAL SOLUTIONS, LLC, KY | $852,320 | ZRG1 |
| 2020 | Novel Algorithms for Reducing Radiation Dose of CT Perfusion2R44EB024438-03 | ALGER, JEFFRY RWANG, DANNY JJ | HURA IMAGING, INC, CA | $820,709 | ZRG1 |
| 2020 | Broad Spectrum Bitter Taste Antagonists Discovery2R42DC017693-02A1 | RAWSON, NANCY ELLENREED, DANIELLE RENEESCHWIEBERT, ERIK MILLS | DISCOVERYBIOMED, INC., AL | $816,655 | ZRG1 |
| 2020 | A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies2R42DK120253-02 | GAUT, JOSEPH P | NEWVENTUREIQ, LLC, MO | $811,695 | ZRG1 |
| 2020 | Wearable shear-wave tensiometry for tracking tendon load during dynamic movement2R42AR074897-02 | ADAMCZYK, PETER GTHELEN, DARRYL G | DESIGN CONCEPTS, INC, WI | $805,387 | ZRG1 |
| 2020 | Magnetic levitation motor for pediatric cardiac and cardiopulmonary therapies - Phase II2R42HL134455-04 | CAHALAN, PATRICK THOMAS | ENSION, INC., PA | $798,861 | ZRG1 |
| 2020 | Caduceus Quest: An interactive digital media resource to promote knowledge of reproductive health and STEM2R44GM133290-02A1 · under PA-18-575 | GILLIAM, MELISSA L.PARSONS, TIMOTHY | RESILIENT GAMES STUDIO, LLC, IL | $781,659 | ZRG1 |
| 2020 | Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing2R42GM116479-02A1 · under PA-18-575 | MEYSTRE, STEPHANE | CLINACUITY,INC., SC | $759,330 | ZRG1 |
| 2020 | Development of Drug Delivery Technology for Stem Cell Based TMJ Regeneration2R42DE028215-02A1 | CHEN, MOEMBREE, MILDRED CHRISTINE | WNT SCIENTIFIC, LLC, NY | $752,047 | ZRG1 |
| 2020 | Single application thixotropic antibiotic delivery systems for otitis externa2R42DC017641-02A1 | SERBAN, MONICA ANDREA | PROMILIAD BIOPHARMA, INC., MT | $751,069 | ZRG1 |
| 2020 | A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement2R42HL134418-03A1 · under PA-18-575 | BLUESTEIN, DANNY | POLYNOVA CARDIOVASCULAR, INC, NY | $719,175 | ZRG1 |
| 2020 | Image Analysis Tools for mpMRI Prostate Cancer Diagnosis Using PI-RADS2R42CA224888-03A1 | ONOFREY, JOHN AARON | EIGEN HEALTH SERVICES LLC, CA | $700,836 | ZRG1 |
| 2020 | Integrated Platform for Mass-Spectrometric Studies of Protein Structure2R42GM121133-02 · under PA-18-575 | BERN, MARSHALL WAYNE | PROTEIN METRICS, LLC, CA | $613,930 | ZRG1 |
| 2020 | A youth-specific helmet for preventing traumatic brain injury1R43NS119134-01 | CAMARILLO, DAVIDGRANT, GERALD ARTHUR | SAVIOR BRAIN INC., VA | $587,742 | ZRG1 |
| 2020 | CNS Gene Therapy for CLN2 Disease Using Parallel Multiple Routes of Administration1R41NS117265-01 | CRYSTAL, RONALD G | LEXEO THERAPEUTICS, LLC, NY | $499,916 | ZRG1 |
| 2020 | Salmonella typhimurium-based Bacteriotherapy for Orphan Benign Tumors: Neurofibromatosis Type II (NF2)1R41NS120338-01 | BRENNER, GARY JAYLUO, SUSAN X | MULBERRY BIOTHERAPEUTICS, INC., MA | $499,527 | ZRG1 |
| 2020 | Recombinant Fc fusions for treatment of uropathogenic E. coli1R41DK122933-01A1 | SOKURENKO, EVGENI VENIAMINOVICWYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $486,870 | ZRG1 |
| 2020 | Transposon Engineered B Cell Therapy for Hunter Syndrome1R43NS120264-01A1 | HAMPE, CHRISTIANE SMCIVOR, R. SCOTT | IMMUSOFT CORPORATION, WA | $466,804 | ZRG1 |
| 2020 | Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension1R41HL152921-01 | ENIKA, NAGABABU | TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC, AL | $465,219 | ZRG1 |
| 2020 | Microbial Synthesis of Therapeutic Bile Acids1R41NS113732-01A1 | LIAO, DEZHILOW, WALTER CSMANSKI, MICHAEL J | METSELEX, INC., MN | $450,234 | ZRG1 |
| 2020 | A novel role for Reelin therapeutics in inflammatory bowel disease1R41DK126520-01 | GONIAS, STEVEN L.KOUNNAS, MARIA Z | REELIN THERAPEUTICS, INC., CA | $400,032 | ZRG1 |
| 2020 | Oleocanthal functional food products for breast cancer recurrence control1R41CA247025-01A1 | EL SAYED, KHALID A | OLEOLIVE, INC., LA | $399,999 | ZRG1 |
| 2020 | Efficacy of a novel small-molecule splicing modulator in chronic lymphocytic leukemia (CLL)1R41CA254498-01A1 | MORRIS, STEPHAN WADESHI, HUIDONGWEBB, THOMAS ROY | WILDFLOWER BIOPHARMA INC, CA | $399,999 | ZRG1 |
| 2020 | Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers1R41CA250707-01 | HOLTSBERG, FREDERICK WAYNESINTIM, HERMAN O | KINARX, LLC, MD | $399,933 | ZRG1 |
| 2020 | Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin1R41CA243954-01A1 | SHAFIRSTEIN, GAL | POP BIOTECHNOLOGIES, INC, NY | $399,917 | ZRG1 |
| 2020 | Inhibition of breast cancer cell metastases using a connexin43 mimetic peptide1R41CA250874-01 | LAMOUILLE, SAMY | ACOMHAL RESEARCH, INC., VA | $399,878 | ZRG1 |
| 2020 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma1R41CA250616-01A1 | BAR-SAGI, DAFNAMORGAN, GARETH JOHNRAMIREZ, CRAIG PATRICK | TEZCAT LABORATORIES LLC, CT | $399,877 | ZRG1 |
| 2020 | Nucleotide inhibitors as precision medicine in breast cancer1R41CA257002-01 | POMERANTZ, RICHARD T | RECOMBINATION THERAPEUTICS, LLC, PA | $399,757 | ZRG1 |
| 2020 | Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma1R41CA250892-01 | LI, XINSAXENA, DEEPAK | PERIOMICS CARE, LLC, NY | $399,752 | ZRG1 |
| 2020 | Development of a Novel Therapeutic Transporter to Treat Metastatic Cancers1R41CA257020-01 | KLEMKE, RICHARD L. | CYTONUS THERAPEUTICS, INC., OH | $399,346 | ZRG1 |
| 2020 | Simplified Transfemoral Carotid Angioplasty and Stenting Under FlowReversal Using a Novel Combination Access Sheath/Balloon System1R41HL152873-01A1 | KALLMES, DAVID F | MARBLEHEAD MEDICAL, LLC, MN | $398,081 | ZRG1 |
| 2020 | Development of gene therapy product for treating MPS IIIB1R41NS115232-01A1 | FU, HAIYAN | NEUROGT, INC., NC | $397,823 | ZRG1 |
| 2020 | Examination of a novel potential therapy for autonomic dysreflexia1R41NS117205-01 | RUPNIAK, NADIA MELANIE JOSEPHINE | DIGNIFY THERAPEUTICS, LLC, NC | $394,754 | ZRG1 |
| 2020 | Development of CA-IL-12 for Triple Negative Breast Cancer1R41CA250887-01 | KLEMKE, RICHARD L. | CYTONUS THERAPEUTICS, INC., OH | $386,586 | ZRG1 |
| 2020 | Refinement of a rapid saliva miRNA diagnostic test for concussion1R42NS119119-01 | LEVITSKIY, DAVIDWRIGHT, FORREST | QUADRANT BIOSCIENCES, INC., NY | $380,848 | ZRG1 |
| 2020 | SciDAP: a next generation universal platform for collaborative data analysis1R41HG011219-01A1 | BARSKI, ARTEMKARTASHOV, ANDREY | DATIRIUM, LLC, OH | $374,500 | ZRG1 |
| 2020 | Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas1R41CA246902-01A1 | CHEN, THOMAS C. | NEONC TECHNOLOGIES, INC., CA | $336,000 | ZRG1 |
| 2020 | Real-time Multimodal Diffuse Reflectance and Polarization Imaging Based Nerve Identification in Surgical Field of View1R41EB029888-01A1 | BABA, JUSTIN | YAYA SCIENTIFIC, LLC, TN | $333,355 | ZRG1 |
| 2020 | Inhaled Fasudil and DETA NONOate CAR-Targeted Liposomes for PAH1R42HL151045-01 · under PA-18-575 | AHSAN, FAKHRUL | VASCULAR BIOSCIENCES, CA | $330,004 | ZRG1 |
| 2020 | Decellularized xenograft leaflet patch for pulmonary valve repair in pediatric patients1R41EB031594-01 | VYAVAHARE, NAREN R | ANNOVIANT, INC, GA | $327,779 | ZRG1 |
| 2020 | Targeted delivery of amiodarone to the heart for atrial fibrillation utilizing novel cardiac targeting peptides1R41HL150908-01A1 | ZAHID, MALIHA | VIVASC THERAPEUTICS INC., PA | $327,289 | ZRG1 |
| 2020 | Cerenkov Multi-Spectral Imaging (CMSI) for Adaptation and Real-Time Imaging in Radiotherapy1R41CA243722-01A1 | EL NAQA, ISSAM M. | ENDECTRA, LLC, MI | $327,240 | ZRG1 |
| 2020 | Photo-mediated ultrasound therapy for treatment of cutaneous vascular malformations1R41EB030875-01 | WANG, XUEDINGYANG, XINMAI | PHOTOSONOX LLC, MI | $325,355 | ZRG1 |
| 2020 | Engineering probiotic yeast for efficient sulforaphane delivery1R43AT011168-01 | DENBY, CHARLES | BERKELEY FERMENTATION SCIENCE INC., CA | $325,000 | ZRG1 |
| 2020 | RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community1R41AG066238-01A1 | FOWLER, NICOLE R. | EPERTURE, LLC, IN | $316,895 | ZRG1 |
| 2020 | Contamination resistant interconnection for reducing peritoneal dialysis - associated peritonitis1R41DK126586-01A1 | VIKER, TOM | CEROVATIONS, LLC, MN | $314,354 | ZRG1 |
| 2020 | A novel device for cervical insufficiency in pregnant women1R41HD102268-01A1 | CRAIGO, SABRINA | CX THERAPEUTICS, INC, MA | $312,578 | ZRG1 |
| 2020 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis1R41EY030391-01A1 · under PA-18-575 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $309,102 | ZRG1 |
| 2020 | Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics1R41DA051309-01 | PAPPAS, GEORGE | SCHEDULE 1 THERAPEUTICS, INC., IL | $308,465 | ZRG1 |
| 2020 | Soft LXR Agonists for Idiopathic Pulmonary Fibrosis1R41HL154852-01 | SUMMER, ROSS S | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $306,500 | ZRG1 |
| 2020 | An Economical Point-of-Care Software Solution Prototype for Medication Prior Authorization1R41MH124600-01 | SALZBRENNER, STEPHEN | BREEZMED, LLC, NE | $301,383 | ZRG1 |
| 2020 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis1R42HL152888-01 | GARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $300,001 | ZRG1 |
| 2020 | Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections1R41AI145759-01A1 · under PA-18-575 | SPELLBERG, BRAD J | EXBAQ LLC, MD | $300,000 | ZRG1 |
| 2020 | Tumor bed implant for simultaneous heat and radiation of resectable brain tumors1R41CA239815-01A1 · under PA-18-575 | STAUFFER, PAUL RATH | MAE CONSULTING GROUP LLC, NH | $300,000 | ZRG1 |
| 2020 | Development of Broad Spectrum Antifungal Agents1R41AI149960-01 · under PA-18-575 | WRIGHT, DENNIS L. | QUERCUS MOLECULAR DESIGN, LLC, CT | $300,000 | ZRG1 |
| 2020 | Antimetabolites for Acute Myeloid Leukemias1R41CA247113-01 · under PA-18-575 | WRIGHT, DENNIS L. | QUERCUS MOLECULAR DESIGN, LLC, CT | $300,000 | ZRG1 |
| 2020 | Regenerative Therapy for Corneal Endothelial Dystrophies and Injuries1R42EY031196-01 · under PA-18-575 | DAS, HIRANMOY | RASHMIVU, LLC, OH | $300,000 | ZRG1 |
| 2020 | Engineering a unique antibody for patients with RA1R41AI147697-01A1 | MARUYAMA, TOSHIAKISHAHRARA, SHIVA | ABWIZ BIO, INC., CA | $300,000 | ZRG1 |
| 2020 | Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections1R41AI152873-01 | PIERCE, JOSHUA G. | SYNOXA SCIENCES, INC, NC | $300,000 | ZRG1 |
| 2020 | Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines1R41AI150232-01A1 | HARTIGAN-O'CONNOR, DENNIS J. | TENDEL THERAPIES INC., CA | $300,000 | ZRG1 |
| 2020 | PROTACS Against Nef as a Functional Cure for HIV Infection1R41AI155054-01 | SMITHGALL, THOMAS E. | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $300,000 | ZRG1 |
| 2020 | Novel strategy to block AAV neutralizing anitbody activity1R41AI155038-01 | LI, CHENGWEN | NABGEN, INC., NC | $300,000 | ZRG1 |
| 2020 | ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung1R42AI155107-01 | TARRAN, ROBERT | ELDEC PHARMACEUTICALS, INC., NC | $300,000 | ZRG1 |
| 2020 | Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles1R41AI155031-01 | ATHANASIOU, MARIA CONSTANCESKINNER, PAMELA J | MARPAM PHARMA, LLC, MN | $300,000 | ZRG1 |
| 2020 | Prevention of GVHD by a probiotic exopolysaccharide.1R41AI155281-01 | KNIGHT, KATHERINE L.OSBORNE, BARBARA A | HASENTECH, INC., IL | $300,000 | ZRG1 |
| 2020 | Intrapartum Transabdominal Fetal Pulse Oximetry: Demonstration in Ewe Models1R41HD104537-01 | GHIASI, SOHEIL | STORX TECHNOLOGIES, INC., CA | $300,000 | ZRG1 |
| 2020 | Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis1R41AI149809-01A1 | KRAUS, CARL NEIL | ARREVUS, INC., NC | $299,999 | ZRG1 |
| 2020 | Enabling comprehensive diagnosis of sub-acute infection in chronic respiratory disease via high sensitivity next generation sequencing1R41AI154380-01 | FINGERLIN, TASHA E.O'CONNOR, BRIAN P | PEAK DIAGNOSTIC PARTNERS LLC, CO | $299,999 | ZRG1 |
| 2020 | Development of Dietary Quercetin to Treat Muscle Wasting Disorders1R43AT011171-01 | VANDERVEEN, BRANDONVELAZQUEZ, KANDY T | ACEPRE, LLC, SC | $299,998 | ZRG1 |
| 2020 | Development of a biomarker panel for minimally-invasive screening and diagnosis of gynecological disease1R41HD104402-01 | REVA, BORIS | MDDX, INC., NY | $299,998 | ZRG1 |
| 2020 | Developing high throughput measurement of thiopurine in DNA by mass spectrometry1R41GM136093-01 · under PA-18-575 | TAO, W. ANDY | TYMORA ANALYTICAL OPERATIONS, LLC, IN | $299,975 | ZRG1 |
| 2020 | Development of an innovative diabetes therapeutic via GPER targeting1R41DK122856-01A1 | ELLING, JOHN | GPER G-1 DEVELOPMENT GROUP LLC, NM | $299,952 | ZRG1 |
| 2020 | Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses1R41AI152745-01A1 | AMARASINGHE, GAYA K.HOLTSBERG, FREDERICK WAYNE | INTEGRATED BIOTHERAPEUTICS, INC., MD | $299,939 | ZRG1 |
| 2020 | DFMO Therapy for Polycystic Kidney Disease1R41DK125183-01A1 | VITEK, MICHAEL PETER | RESILIO THERAPEUTICS, LLC, NC | $299,934 | ZRG1 |
| 2020 | Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries1R41HL151025-01 · under PA-18-575 | BOIRE, TIMOTHY C | VENOSTENT, INC., TX | $299,910 | ZRG1 |
| 2020 | Q-GRFT Enema Development Supporting a Multi-Administration Clinical Study1R41AI152919-01 | TUSE, DANIEL | GROW BIOMEDICINE LLC, CA | $299,874 | ZRG1 |
| 2020 | Evaluation of a peptide that inhibits the activation of NOX2 and the generation of reactive oxygen species in protection against acute lung injury1R41HL145848-01A1 · under PA-18-575 | FEINSTEIN, SHELDON IFISHER, ARON B. | PEROXITECH, LLC, PA | $299,866 | ZRG1 |
| 2020 | Non-Invasive Oropharynx Appliance to Maintain Airway Patency1R41HL150933-01 · under PA-18-575 | DURAND, DOMINIQUE M | ANEMED INC, OH | $299,743 | ZRG1 |
| 2020 | Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?1R42AI155275-01 | SACHA, JONAH B.WATKINS, DAVID I | MABLOC, LLC, DC | $299,598 | ZRG1 |
| 2020 | Using Targeted Lipid Nanoparticles to Deliver Chemotherapeutic Agents against Pancreatic Cancer1R41CA247009-01 · under PA-18-575 | LAMBROS, MARIA | DORICPHARMA LLC, CA | $299,559 | ZRG1 |
| 2020 | Inhibitors of T3SS translocon assembly to combat multi-drug resistant P. aeruginosa1R41AI149922-01 · under PA-18-575 | HEUCK, ALEJANDRO PABLOMOIR, DONALD T | MICROBIOTIX, INC, MA | $299,449 | ZRG1 |
| 2020 | Vaccination against Zika virus infection using mosquito NeSt1 protein1R41AI152904-01A1 | LEDIZET, MICHEL | L2 DIAGNOSTICS, LLC, CT | $299,200 | ZRG1 |
| 2020 | Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)1R41AI149940-01 · under PA-18-575 | AUCOIN, DAVID PRAYCHAUDHURI, SYAMAL X | INBIOS INTERNATIONAL, INC., WA | $299,112 | ZRG1 |
| 2020 | Next-generation precision medicine for targeting recombination-deficient cancers1R41CA239983-01A1 · under PA-18-575 | POMERANTZ, RICHARD T | RECOMBINATION THERAPEUTICS, LLC, PA | $298,959 | ZRG1 |
| 2020 | Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia1R41CA250761-01A1 | CAO, PING | BRIDGENE BIOSCIENCES, INC., CA | $298,928 | ZRG1 |
| 2020 | Multiplexed Bioassay for Checkpoint Inhibitor Autoimmunity1R41AI149951-01 · under PA-18-575 | MAMULA, MARK J | L2 DIAGNOSTICS, LLC, CT | $298,911 | ZRG1 |
| 2020 | Preclinical proof of concept validation of a novel endoscopic treatment for urethral stricture disease1R41DK125209-01A1 | GODZICH, CHANYA | CELEFLUX LLC, MD | $298,531 | ZRG1 |
| 2020 | New Inhibitors of HIV latency reactivation1R41AI152860-01 | KARN, JONATHANSHORTRIDGE, MATTHEW DEANVARANI, GABRIELE | ITHAX PHARMACEUTICALS, INC., WA | $298,410 | ZRG1 |
| 2020 | Development of Single Agent Antibiofilm Antibiotics1R41AI155280-01 | PIERCE, JOSHUA G. | SYNOXA SCIENCES, INC, NC | $298,326 | ZRG1 |
| 2020 | Development of a Lighted Infusion Line to Enhance Pediatric Critical Care1R41HD104560-01 | CALAMARO, CHRISTINA JOY | CHS HEALTHCARE VENTURES, INC, GA | $298,099 | ZRG1 |
| 2020 | Novel AMPK Activators for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus1R41DK127798-01 | KLEIN, JANET D.SANDS, JEFF M | NEPHRODI THERAPEUTICS, INC., WA | $297,609 | ZRG1 |
| 2020 | Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood.1R41GM136084-01 · under PA-18-575 | MILLER, CASS T | REDBUD LABS, INC., NC | $296,954 | ZRG1 |
| 2020 | Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD1R41DK127869-01 | HOLLAND, GEORGEWOODSIDE, DARREN G | AVIARA PHARMACEUTICALS, INC., TX | $296,724 | ZRG1 |
| 2020 | Non-Immunogenic PEG-like Conjugates of Uricase1R41TR003255-01 | HUCKNALL, ANGUS | GATEWAY BIO, INC., NC | $288,472 | ZRG1 |
| 2020 | Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells1R41AI149920-01 · under PA-18-575 | GALARZA-MUNOZ, GADDIEL | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC., TX | $283,667 | ZRG1 |
| 2020 | Development of a vaccine to prevent Pneumocystis pneumonia1R41AI145416-01A1 · under PA-18-575 | DOWNES, MICHAEL ROBERTNORRIS, KAREN A | NXT BIOLOGICS, INC., GA | $272,439 | ZRG1 |
| 2020 | Preventing liver fibrosis in alcoholic hepatitis by enhancing liver regenerative capacity via transient telomere extension using lipid nanoparticle-encapsulated TERT mRNA1R41AA028749-01 | RAMUNAS, JOHN | REJUVENATION TECHNOLOGIES, INC., CA | $272,403 | ZRG1 |
| 2020 | Multi NA-based influenza vaccines1R41AI152800-01 | KANG, SANG-MOO | ADVAC, LLC, GA | $272,223 | ZRG1 |
| 2020 | Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP)1R41HD101202-01A1 | AHMED, MOHAMEDGARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $265,096 | ZRG1 |
| 2020 | Enabling the repurposing of niclosamide for castrate-resistant prostate cancer using a novel formulation technology platform1R41CA243931-01A1 | WILLIAMS, ROBERT O. | VIA THERAPEUTICS, LLC, TX | $263,895 | ZRG1 |
| 2020 | FH-Fc as a Pre-Exposure Prophylactic for Tickborne Disease1R41AI152954-01A1 | WYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $262,947 | ZRG1 |
| 2020 | Development of wearable technology to enable therapy personalization of 177Lu DOTATATE for neuroendocrine tumors1R41CA243982-01A1 | PIERCE, LARRY | PRECISION SENSING, LLC, WA | $262,921 | ZRG1 |
| 2020 | Antioxidant enzyme-loaded Pro-NP for treatment of TBI.1R41NS119082-01 | KIEVIT, FORREST MMADSEN, GARY LEONARD | PROTRANSIT NANOTHERAPY, LLC, NE | $259,938 | ZRG1 |
| 2020 | Autonomous RNA-Mediated Anti-Influenza A Virus Therapeutics (AMRed Therapeutics)1R41AI147902-01A1 | HOUSER, BRANDY LYNNTENOEVER, BENJAMIN R. | CELDARA MEDICAL, LLC, NH | $258,360 | ZRG1 |
| 2020 | OBJECTIVE HOME MANAGEMENT OF PEDIATRIC ASTHMA EXACERBATION USING MOBILE TECHNOLOGY AND MACHINE LEARNING1R41NR019735-01 | PATEL, SHILPASHEKHAR, RAJ | AUSCULTECH DX, LLC, MD | $257,878 | ZRG1 |
| 2020 | A novel non-invasive method of aspiration detection in preterm infants.1R41HD104305-01 | MCGRATTAN, KATLYN ELIZABETH | NUBORN MEDICAL, INC., MN | $255,998 | ZRG1 |
| 2020 | Intraoperative Analytics and Enhanced Patient Outcomes1R41TR003249-01 | CORR, STUART JAMESMACGILLIVRAY, TOMMECCA, JOSHUA | M&S BIOTICS, INC., TX | $255,719 | ZRG1 |
| 2020 | Advancing Small Molecule Read Through Compounds to Prevent and/or Treat Heritable Pulmonary Artery Hypertension1R41HL152915-01 | REHAN, VIRENDER K | ADVENT THERAPEUTICS, INC., PA | $252,131 | ZRG1 |
| 2020 | Development of a prototype software for automated PET/CT interpretation and reporting in thoracic cancer1R41CA236492-01A1 | UDUPA, JAYARAM K | QUANTITATIVE RADIOLOGY SOLUTIONS, LLC, PA | $252,131 | ZRG1 |
| 2020 | Novel OCT Technology for Detection of Occult Sperm in the Testes in Non- Obstructed Azoospermia.1R41HD102275-01 | SWERDLOFF, RONALD | UNASPER, INC., CA | $252,130 | ZRG1 |
| 2020 | Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments1R41AI152915-01 | MANOHAR, MURLI | ASCRIBE BIOSCIENCE INC., NY | $252,130 | ZRG1 |
| 2020 | Improving data capture in clinical research using a chatbot1R41LM013419-01 | WELCH, BRANDON M | DOKBOT, LLC, NY | $252,130 | ZRG1 |
| 2020 | Targeted Therapies for the Treatment of GI-ARS Diarrhea1R41DK125208-01 | TIGYI, GABOR J | RXBIO, INC., TN | $252,128 | ZRG1 |
| 2020 | Isotopically Labeled Heparan Sulfate Glycosaminoglycan Disaccharides for use as Internal Standards1R41GM139440-01 | ORLANDO, RON | GLYCOSCIENTIFIC, LLC, GA | $252,114 | ZRG1 |
| 2020 | Development and Commercialization of a Sample Preparation System for Time Resolved Cryo-Electron Microscopy1R42GM139495-01 | FRANK, JOACHIMSALMON, NORMAN JAMES | HUMMINGBIRD PRECISION MACHINE COMPANY, WA | $252,105 | ZRG1 |
| 2020 | Determination of circulation factors that mediate the health benefits of exercise in mitochondrial aging1R41AG065131-01A1 | PROLLA, TOMAS ALBERTO | CYTEGEN CORPORATION, CO | $252,092 | ZRG1 |
| 2020 | STING Activators as Therapy for Cancer1R41CA250629-01A1 | BARBER, GLEN N | STINGINN, LLC, FL | $252,064 | ZRG1 |
| 2020 | Gene Therapy to Treat Ethanol-induced Osteoporosis Associated with Aldehyde Dehydrogenase 2 Deficiency1R41AA028465-01 | CRYSTAL, RONALD G | LEXEO THERAPEUTICS, LLC, NY | $252,042 | ZRG1 |
| 2020 | Nature-inspired Aqueous Biodegradable Adhesives for Abdominoplasty1R41EB030462-01 | LIU, CHAORAVNIC, DINO J | ALEO BME, INC., PA | $251,989 | ZRG1 |
| 2020 | Dianomi Therapeutics - Using Mineral Coated Microparticles as an Improved Sustained Delivery Method of Anakinra for Treatment and Prevention of Gout with a Single Injection1R41AR078063-01A1 | CHAMBERLAIN, CONNIE SCLEMENTS, ANNA ELIZABETH | DIANOMI THERAPEUTICS, INC., WI | $251,880 | ZRG1 |
| 2020 | Step UP for STEM and Health Careers: An Intervention to Reduce STEM related biases towards young women and minorities1R41HD103517-01 | GILLIAM, MELISSA L.PARSONS, TIMOTHY | RESILIENT GAMES STUDIO, LLC, IL | $251,344 | ZRG1 |
| 2020 | Chemically controlling chromatin to treat Friedriech's Ataxia1R41TR003245-01 | HATHAWAY, NATHANIEL A. | EPIGENOS BIOSCIENCE, INC., NC | $251,236 | ZRG1 |
| 2020 | A Novel Strategy for Diagnosis of Esophageal Adenocarcinoma.1R41CA250779-01 | LUNZ, DANIEL GREGORY | CAPSULOMICS, LLC, MD | $250,764 | ZRG1 |
| 2020 | High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines1R42TR002798-01A1 | BERGMAN, NICOLECHATTERJEE, SASWATITAI, YU-CHONG | XDEMICS CORPORATION, CA | $250,241 | ZRG1 |
| 2020 | A Vaccine for Acute Flaccid Myelitis1R41AI155100-01 | ANDINO, RAUL | ALEPH THERAPEUTICS, INC., CA | $250,215 | ZRG1 |
| 2020 | Hemoglobin-based antidotes for the treatment of carbon monoxide poisoning1R42ES031993-01 · under PA-18-575 | ROSE, JASON JTEJERO BRAVO, JESUS | GLOBIN SOLUTIONS, INC., PA | $249,993 | ZRG1 |
| 2020 | Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion1R41HL152923-01A1 | LI, CHENGWEN | BEDROCK THERAPEUTICS, INC., NC | $249,310 | ZRG1 |
| 2020 | Small molecule inhibitors of oncogenic miR-211R41CA254746-01 | CALIN, GEORGE A.VARANI, GABRIELE | ITHAX PHARMACEUTICALS, INC., WA | $249,109 | ZRG1 |
| 2020 | Therapeutic targeting of Nox2 and Nox4 in Duchenne Muscular Dystrophy1R41HL151043-01A1 | HECKER, LOUISE | FIBRONOX, L.L.C., AZ | $248,019 | ZRG1 |
| 2020 | Feasibility Study of HIF2A Inhibitor PT2385 to Treat Muscle Strain Injury1R41OD030519-01 | YIN, AMELIAYIN, HANG | HAWA THERAPEUTICS LLC, GA | $245,050 | ZRG1 |
| 2020 | Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss1R41DK127817-01 | SAWYER, TOMI K | COURAGE THERAPEUTICS, INC., MA | $244,905 | ZRG1 |
| 2020 | Development of a Rapid Low-Cost Fecal-based TB Diagnostic for Children1R41AI155206-01 | CIRILLO, JEFFREY D. | PULMONESCENCE DIAGNOSTICS, INC., TX | $243,960 | ZRG1 |
| 2020 | Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation1R41MD015689-01 | SMITH, DEREK T.TODD, RUSSELL NATHANZHU, QIN | MOVE, LLC, WY | $242,114 | ZRG1 |
| 2020 | Development of a New Treatment for Diabetic Wounds1R41DK125213-01A1 | NAIR, SREEJAYAN | NUTRIWYO, LLC, WY | $241,148 | ZRG1 |
| 2020 | Hybrid nanoparticles as highly efficient photosensitizers for the treatment of topical bacterial infections1R41AI150075-01A1 | ZHANG, PENG | ALPH TECHNOLOGIES, LLC, OH | $241,018 | ZRG1 |
| 2020 | Enabling membrane protein structural analysis: Tools for capillary diffusion crystallization and remote in situ diffraction experiments1R41GM139420-01 | HOWELLS, RICHARD WILLIAM | ELK VALLEY ENTERPRISES, INC., PA | $239,206 | ZRG1 |
| 2020 | Feelix @ Home: Testing and optimization of a smart stethoscope for home use to monitor changes in lung status of individuals with chronic conditions1R42HL147728-01A1 · under PA-18-575 | BUSCH-VISHNIAC, ILENE JOYELHILALI, MOUNYA | SONAVI LABS, INC., MD | $236,489 | ZRG1 |
| 2020 | Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents1R41CA247058-01 · under PA-18-575 | MISHRA, SANKET | GRANNUS THERAPEUTICS LLC, IN | $233,195 | ZRG1 |
| 2020 | A Novel Therapeutic Agent for the Treatment of Gram-positive Infections1R41AI149803-01A1 | SMITH, JAMES LEIF | SANO CHEMICALS, INC, TX | $233,066 | ZRG1 |
| 2020 | Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities1R41MD015915-01 | SHAH, SWATI | FETAL LIFE, LLC, KY | $232,315 | ZRG1 |
| 2020 | Novel QcrB Inhibitors for the Treatment of Tuberculosis1R41AI145514-01A1 · under PA-18-575 | HIPSKIND, PHILIP ARTHUR | LGENIA, INC., IN | $225,343 | ZRG1 |
| 2020 | A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation1R41EY030382-01A1 · under PA-18-575 | GRAMATIKOV, BORISSHAKA, JUSTIN | REBISCAN, LLC, MA | $225,000 | ZRG1 |
| 2020 | A platform for engineering peptide ligase for building next generation peptide therapeutics.1R41GM136037-01 · under PA-18-575 | ABATE, ADAM R. | SCRIBE BIOSCIENCES, INC., CA | $225,000 | ZRG1 |
| 2020 | Novel Nanosecond Laser and Ultrasound to Selectively Treat Eye Blood Vessels1R41EY031219-01 · under PA-18-575 | PAULUS, YANNIS MANTAS | PHOTOSONOX LLC, MI | $225,000 | ZRG1 |
| 2020 | Pharmacological chaperones for the treatment of Open-Angle Glaucoma1R41EY031203-01 · under PA-18-575 | MAKLEY, LEAH NICOLE | VIEWPOINT THERAPEUTICS, INC., CA | $225,000 | ZRG1 |
| 2020 | Portable, affordable, quantitative microchip electrophoresis system for integrated anemia and hemoglobin variant testing1R41HL151015-01 · under PA-18-575 | GALEN, PETER | HEMEX HEALTH, INC., OR | $225,000 | ZRG1 |
| 2020 | Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure1R41HL151235-01 · under PA-18-575 | ROY-CHAUDHURY, PRABIRRYCHNOVSKY, STEVEN | ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., CA | $225,000 | ZRG1 |
| 2020 | CD73 for sepsis1R41AI149789-01A1 | HASKO, GEORGE | PURINE PHARMACEUTICALS, INC., NJ | $225,000 | ZRG1 |
| 2020 | MR Virtual Pathology of the Prostate1R41CA244056-01A1 | KARCZMAR, GREGORY S.MUSTAFI, DEVKUMAROTO, AYTEKIN | QMIS, LLC, IL | $225,000 | ZRG1 |
| 2020 | Stress forces huESC differentiation; confirmation as an accurate DevTox HTS1R41ES031451-01A1 | ABDULHASAN, MOHAMMEDRAPPOLEE, DANIEL ALLEN | REPRODUCTIVE STRESS; MEASUREMENT, MECHANISMS AND MANAGEMENT, CORPORATION, MI | $225,000 | ZRG1 |
| 2020 | The MICELI Aggregometer: a Point-of-Care Platelet Function Analyzer1R41HL147807-01A1 | LADUCA, FRANKSLEPIAN, MARVIN J | PLAKDX, LLC, AZ | $225,000 | ZRG1 |
| 2020 | MITOCHONDRIAL RESPIROMETRY IN FROZEN BIOLOGICAL SAMPLES1R41ES031043-01A1 | SHIRIHAI, ORIAN SWANG, AMY | ENSPIRE BIO, INC., CA | $225,000 | ZRG1 |
| 2020 | HIV Research Social and Behavioral Instruments (SABI) Library and Project Management Software System1R41MH123287-01A1 | STELTER, REBECCA LYNN | INNOVATION RESEARCH AND TRAINING, INC., NC | $224,999 | ZRG1 |
| 2020 | Development of EFTX-001 to target KRAS mutations in cancer1R41CA246848-01 · under PA-18-575 | PECOT, CHAD V | ENFUEGO THERAPEUTICS INC., NC | $224,995 | ZRG1 |
Showing the 200 most recent of 1,360 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.